Amol Akhade, Senior Consultant at Fortis Hospitals Mumbai, shared a post on LinkedIn:
“Key Trials to Watch at WCLC 2025.
The lung cancer field continues to evolve rapidly, and this year’s WCLC brings several late-breaking plenary presentations and practice-changing phase III trials that deserve attention.
Plenary Late-Breakers
FLAURA2 (Phase III) – Osimertinib + chemotherapy vs osimertinib alone. Long-awaited overall survival update in EGFR-mutant NSCLC.
Aumolertinib + Chemotherapy (Phase III) – An important trial in 1L EGFR-mutant NSCLC, with potential to influence both Chinese and global standards.
HARMONi-A (Phase III) – Ivonescimab (PD-1/VEGF bispecific) + chemo vs placebo + chemo in EGFR-mutant NSCLC post-TKI. A novel strategy moving to the main stage.
ARROS-1 (Pivotal) – Zidesamtinib, a next-generation ROS1 inhibitor, delivering registrational data in ROS1+ NSCLC.
CheckMate 816 (Phase III) – Nivolumab + chemo in the neoadjuvant setting now with definitive OS data.
EA5181 (Phase III) – Durvalumab during concurrent chemoradiation, followed by consolidation durvalumab in unresectable stage III NSCLC. May shift the paradigm in locally advanced disease.
NADIM Adjuvant (Phase III) – Nivolumab + chemo vs chemo in the adjuvant setting, a crucial step after NADIM I and II.
Other Notable Phase III Readouts
IMforte (Phase III) – Lurbinectedin + atezolizumab in extensive-stage SCLC.
Rezivertinib (Phase III) – A new-generation EGFR TKI post-3G TKI failure.
TACTI-004 (Phase III) – Eftilagimod alfa + pembrolizumab (novel IO-IO combo).
ARTEMIDE-Lung02 (Phase III) – Rilimogene immunotherapy combination.
MK-3475A (Phase III) – Subcutaneous pembrolizumab vs IV: a convenience-focused trial with real-world relevance.”
More posts featuring Amol Akhade.
